Swiss Pharma Firm Roche Acquires AI Specialist Pathai

2026-05-07 02:26:02

(MENAFN- Swissinfo) Swiss pharmaceutica giant Roche is expanding in the field of digital pathology with an agreement to acquire United States firm PathAI. Select your language

Generated with artificial intelligence. Listening: Swiss pharma firm Roche acquires AI specialist PathAI This content was published on May 7, 2026 - 16:23 2 minutes Keystone-SDA

Deutsch de Roche übernimmt KI-Spezialisten PathAI Original Read more: Roche übernimmt KI-Spezialisten P

+Get the most important news from Switzerland in your inbox

With this acquisition, Roche aims to expand its position in AI-based diagnostic solutions.

The purchase price is $750 million plus potential milestone payments of up to $300 million, the company announced.

+ Why Roche's supercomputer is a big deal

The combination of PathAI's AI-powered Image Management System (IMS) with Roche's diagnostic expertise is expected to increase the efficiency of laboratories, accelerate the development of new clinical therapies and enable the discovery of new biomarkers and new diagnostic tools.

Roche expects this to be a further step towards personalised medicine.

Roche and PathAI already entered into a collaboration in 2021, which was intensified in 2024. Roche expects the acquisition of PathAI to be completed in the second half of the current year, subject to fulfilment of the usual regulatory and competition law conditions.

Once the transaction closes, Roche intends to integrate PathAI into its own diagnostics division.
More More New treatments Science podcast: the AI revolution in drug development
This content was published on Jan 30, 2026 In episode 4 of the Swiss Connection Science podcast we explore the role of AI in drug development.
Read more: Science podcast: the AI revolution in drug develo

MENAFN07052026000210011054ID1111082849

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.